What is Central Pharmaceutical JSC No2 Earnings Yield (Joel Greenblatt) %?
Central Pharmaceutical JSC No2's Enterprise Value for the quarter that ended in . 20 was ₫0.00 Mil.
Central Pharmaceutical JSC No2 does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Central Pharmaceutical JSC No2's Earnings Yield (Joel Greenblatt) at this moment.
The historical rank and industry rank for Central Pharmaceutical JSC No2's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
HSTC:DP2's Earnings Yield (Joel Greenblatt) % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.66 * Ranked among companies with meaningful Earnings Yield (Joel Greenblatt) % only.
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Central Pharmaceutical JSC No2's Forward Rate of Return (Yacktman) % for the quarter that ended in . 20 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Central Pharmaceutical JSC No2 Earnings Yield (Joel Greenblatt) % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Central Pharmaceutical JSC No2 Earnings Yield (Joel Greenblatt) % Chart
Central Pharmaceutical JSC No2 Annual Data
Trend
Earnings Yield (Joel Greenblatt) %
Central Pharmaceutical JSC No2 Semi-Annual Data
Earnings Yield (Joel Greenblatt) %
Competitive Comparison of Central Pharmaceutical JSC No2's Earnings Yield (Joel Greenblatt) %
For the Pharmaceutical Retailers subindustry, Central Pharmaceutical JSC No2's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Central Pharmaceutical JSC No2's Earnings Yield (Joel Greenblatt) % Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Central Pharmaceutical JSC No2's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Central Pharmaceutical JSC No2's Earnings Yield (Joel Greenblatt) % falls into.
Central Pharmaceutical JSC No2 Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Central Pharmaceutical JSC No2s Earnings Yield (Joel Greenblatt) for the fiscal year that ended in . 20 is calculated as
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Central Pharmaceutical JSC No2 Earnings Yield (Joel Greenblatt) % Related Terms
Thank you for viewing the detailed overview of Central Pharmaceutical JSC No2's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
Central Pharmaceutical JSC No2 (HSTC:DP2) Business Description
Central Pharmaceutical JSC No2 is engaged in the Trading of medicinal materials, pharmaceutical materials, chemicals, essential oils, modern medicines, traditional medicine drugs, cosmetics, and nutritious foods. Some of its products include Gentamycin injection solution 80; Genatreson Skin Cream; Ferimax Hard Capsules and others.
Central Pharmaceutical JSC No2 (HSTC:DP2) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HSTC:DP2 has been successfully added to your